c-Cbl, Polyclonal Antibody

Anti-c-Cbl (Ab-700) Antibody

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

c-Cbl (Ab-700) Antibody detects endogenous levels of total c-Cbl protein.

Affinity purified

Liquid

100ug/100ul (lot specific)

This product is stable for several weeks at 4 degree C as an undiluted liquid. Dilute only prior to immediate use. For extended storage, aliquot contents and freeze at -20 degree C or below. Avoid cycles of freezing and thawing. Expiration date is one (1) year from date of receipt.

Small volumes of anti-c-Cbl antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Immunohistochemistry (IHC)

IHC: 1:50~1:100

99,633 Da

Cbl proto-oncogene, E3 ubiquitin protein ligase

E3 ubiquitin-protein ligase CBL; Cas-Br-M (murine) ecotropic retroviral transforming sequence; RING finger protein 55; casitas B-lineage lymphoma proto-oncogene; fragile site, folic acid type, rare, fra(11)(q23.3); oncogene CBL2; proto-oncogene c-Cbl; signal transduction protein CBL

E3 ubiquitin-protein ligase CBL

CBL_HUMAN

This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Mar 2012]

CBL: an adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling. Participates in signal transduction in hematopoietic cells.

Protein type: Adaptor/scaffold; Motility/polarity/chemotaxis; Ubiquitin ligase; Ubiquitin conjugating system; Ligase; Oncoprotein; EC 6.3.2.19; EC 6.3.2.-

Chromosomal Location of Human Ortholog: 11q23.3

Cellular Component: cytoplasm; plasma membrane; flotillin complex; cytosol; nucleus

Molecular Function: protein binding; signal transducer activity; ephrin receptor binding; phosphotyrosine binding; zinc ion binding; ubiquitin-protein ligase activity; calcium ion binding; transcription factor activity; SH3 domain binding; ligase activity

Biological Process: negative regulation of epidermal growth factor receptor signaling pathway; positive regulation of phosphoinositide 3-kinase cascade; epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; cell surface receptor linked signal transduction; regulation of transcription, DNA-dependent; transforming growth factor beta receptor signaling pathway; protein ubiquitination; positive regulation of receptor-mediated endocytosis; negative regulation of apoptosis

Disease: Noonan Syndrome-like Disorder With Or Without Juvenile Myelomonocytic Leukemia

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.